明目地黄丸联合羟苯磺酸钙治疗Ⅲ期糖尿病性视网膜病变的效果观察  

Effect observation of Mingmu Dihuang Pill combined with calcium hydroxybenzenesulfonate in the treatment of stageⅢdiabetic retinopathy

作　　者：鹿麓[1] LU Lu(Tai'an Maternal and Child Health Hospital,Tai'an 271000,China)

机构地区：[1]泰安市妇幼保健院,271000

出　　处：《中国现代药物应用》2023年第14期151-154,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析对Ⅲ期糖尿病性视网膜病变患者应用明目地黄丸联合羟苯磺酸钙治疗的实际效果。方法134例Ⅲ期糖尿病性视网膜病变患者,根据入院顺序先后分为对照组和观察组,各67例。对照组患者予以羟苯磺酸钙治疗,观察组患者予以明目地黄丸联合羟苯磺酸钙治疗。对比两组患者治疗效果及治疗前后的眼底情况、Log MAR视力、血清细胞因子[血清血管内皮生长因子(VEGF)、胰岛素样生长因子-1(IGF-1)、视黄醇结合蛋白4(RBP4)]。结果治疗后,两组患者出血斑面积、视觉灰度值、血管瘤体积、黄斑厚度均显著小于本组治疗前,且观察组患者出血斑面积(1.10±0.25)mm^(2)、视觉灰度值(1.32±0.24)%、血管瘤体积(10.26±2.22)μm^(3)、黄斑厚度(280.42±15.36)μm小于对照组的(2.06±0.42)mm^(2)、(2.74±0.32)%、(15.22±2.55)μm^(3)、(352.25±20.38)μm,差异有统计学意义(P<0.05)。治疗后,两组患者Log MAR视力均显著优于本组治疗前,且观察组患者Log MAR视力(0.32±0.04)优于对照组的(0.45±0.05),差异有统计学意义(P<0.05)。治疗后,两组患者VEGF、RBP4、IGF-1均显著低于本组治疗前,且观察组患者VEGF(94.52±14.96)pg/ml、RBP4(36.38±3.52)mg/L、IGF-1(114.50±15.32)ng/ml低于对照组的(108.36±17.42)pg/ml、(41.67±3.42)mg/L、(123.94±16.07)ng/ml,差异有统计学意义(P<0.05)。观察组患者治疗总有效率89.55%明显高于对照组的73.13%,差异有统计学意义(P<0.05)。结论针对Ⅲ期糖尿病性视网膜病变患者应用明目地黄丸,羟苯磺酸钙联合治疗效果显著,值得临床推广应用。Objective To analyze the practical effect of Mingmu Dihuang Pill combined with calcium hydroxybenzenesulfonate in the treatment of patients with stageⅢdiabetic retinopathy.Methods A total of 134 patients with stageⅢdiabetic retinopathy were divided into control group and observation group according to the order of admission,with 67 cases in each group.The control group was treated with calcium hydroxybenzenesulfonate,and the observation group was treated with Mingmu Dihuang Pill and calcium hydroxybenzenesulfonate.Both groups were compared in terms of therapeutic effect,fundus conditions,Log MAR visual acuity,serum cytokines[serum vascular endothelial growth factor(VEGF),insulin-like growth factor-1(IGF-1),retinol binding protein 4(RBP4)]before and after treatment.Results After treatment,the hemorrhagic spot area,visual gray value,hemangioma volume and macular thickness in both groups were significantly lower than those before treatment in this group;the observation group had hemorrhagic spot area of(1.10±0.25)mm^(2),visual gray value of(1.32±0.24)%,hemangioma volume of(10.26±2.22)μm^(3),and macular thickness of(280.42±15.36)μm,which were less than those of(2.06±0.42)mm^(2),(2.74±0.32)%,(15.22±2.55)μm^(3),and(352.25±20.38)μm in the control group;the differences were statistically significant(P<0.05).After treatment,Log MAR visual acuity in both groups was significantly better than that before treatment in this group,and Log MAR visual acuity of(0.32±0.04)in the observation group was better than that of(0.45±0.05)in the control group.The difference was statistically significant(P<0.05).After treatment,VEGF,RBP4 and IGF-1 in both groups were significantly lower than those before treatment in this group;the observation group had VEGF of(94.52±14.96)pg/ml,RBP4 of(36.38±3.52)mg/L,and IGF-1 of(114.50±15.32)ng/ml,which were lower than those of(108.36±17.42)pg/ml,(41.67±3.42)mg/L,and(123.94±16.07)ng/ml in the control group;the differences were statistically significant(P<0.05).The total effective

关 键 词：明目地黄丸 羟苯磺酸钙 Ⅲ期糖尿病性视网膜病变 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]